Treatment options for chronic urticaria
Pro Research Analysisby 
Searched over 200M research papers
First-Line Treatment: Second-Generation Antihistamines for Chronic Urticaria
The primary treatment for chronic urticaria is the use of second-generation H1 antihistamines due to their safety and effectiveness. If symptoms persist, the dosage can be increased up to four times the standard recommended dose, as supported by current guidelines and multiple studies Hidvégi2021Asero2013Zuberbier2024+3 MORE. This approach is generally well-tolerated and forms the foundation of chronic urticaria management.
Second-Line and Add-On Therapies: Omalizumab and Cyclosporine
For patients who do not respond to high-dose antihistamines, omalizumab, an anti-IgE monoclonal antibody, is the next recommended step. Omalizumab has shown significant efficacy and safety in both clinical trials and real-world settings, especially for chronic spontaneous urticaria Hidvégi2021Kolkhir2019Asero2013+6 MORE. If omalizumab is ineffective, cyclosporine, an immunosuppressant, can be considered as an add-on therapy Hidvégi2021Asero2013Zuberbier2024+3 MORE.
Additional and Alternative Treatments for Refractory Cases
For patients with chronic urticaria that is resistant to antihistamines and omalizumab, several other options are available, though evidence for their routine use is limited. These include:
- Leukotriene receptor antagonists (e.g., montelukast) Asero2013Staubach2024Antia2018
- Systemic corticosteroids (short-term use for acute exacerbations) Asero2013Hon2019
- Other immunosuppressive drugs such as methotrexate, azathioprine, mycophenolate mofetil, and cyclophosphamide
- Anti-inflammatory agents like dapsone, sulfasalazine, and hydroxychloroquine Asero2013Staubach2024
- Intravenous immunoglobulin in select cases
These treatments are generally reserved for severe, refractory cases and should be used under specialist supervision.
Emerging and Future Therapies: Biologics and Targeted Agents
Research is ongoing into new biologic and small molecule therapies for chronic urticaria. Promising agents in clinical trials include:
- Next-generation anti-IgE monoclonal antibodies (e.g., ligelizumab, UB-221) Kolkhir2019Wedi2022Zuberbier2024+1 MORE
- Anti-cytokine therapies (e.g., dupilumab, mepolizumab, benralizumab, tezepelumab) Kolkhir2019Wedi2022Zuberbier2024
- Bruton’s tyrosine kinase (BTK) inhibitors (e.g., remibrutinib, fenebrutinib) Kolkhir2019Wedi2022Zuberbier2024
- Spleen tyrosine kinase inhibitors and other novel targets Kolkhir2019Wedi2022Zuberbier2024
These emerging treatments aim to address the unmet needs of patients who do not respond to current therapies and may allow for more personalized, endotype-based approaches in the future .
Special Considerations: Comorbidities and Combination Therapies
Patients with chronic urticaria and comorbidities can often be managed safely with combinations of antihistamines, omalizumab, cyclosporine, and other agents. Real-world data suggest that these combinations are feasible and generally have a good safety profile . Treatment should be tailored to individual patient needs, especially in special populations such as children, pregnant women, or those with multiple health conditions Asero2013Zuberbier2024Maurer2015+1 MORE.
Conclusion
Chronic urticaria treatment typically starts with second-generation antihistamines, escalating to higher doses if needed. Omalizumab is the preferred next step for resistant cases, with cyclosporine and other immunosuppressive or anti-inflammatory agents as further options for refractory disease. New biologics and targeted therapies are under development and may soon expand the range of effective treatments, offering hope for patients who do not respond to current options. Personalized treatment strategies are increasingly important to address the diverse mechanisms underlying chronic urticaria Hidvégi2021Kolkhir2019Asero2013+7 MORE.
Sources and full results
Most relevant research papers on this topic
New treatments for chronic urticaria.
New treatments for chronic urticaria, including off-label use of existing drugs and novel therapies in clinical trials, show promise in improving patient outcomes.
DOI